Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT) unveiled the Voyager™ Platform at US HUPO 2026, a benchtop system designed to enable Iterative Mapping of up to 10 billion intact proteins and proteoforms in a single run. The company began an Early Access Program in Jan 2026 and expects commercial launch in late 2026.
Field evaluation at the Buck Institute produced reproducible tau proteoform insights; initial offerings include a Tau Proteoforms assay quantifying up to 768 full-length tau proteoform groups. Limited instrument placements will precede broad commercial availability.
Positive
- Iterative Mapping capacity to measure up to 10 billion intact proteins per run
- Commercial launch targeted in late 2026, providing a clear near-term timetable
- Early Access Program active since Jan 2026 with fee-for-service and guided projects
- Tau Proteoforms assay quantifies up to 768 full-length tau proteoform groups
Negative
- Initial availability limited to fee-for-service and a small number of instrument placements before full launch
- No commercial pricing, volume guidance, or revenue metrics disclosed to assess near-term financial impact
News Market Reaction – NAUT
On the day this news was published, NAUT gained 5.19%, reflecting a notable positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $18M to the company's valuation, bringing the market cap to $366M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: CSBR -1.02%, QNCX -8.3%, EXOZ -7.59% vs IPA +3.5%, SEER +1.98%, while NAUT was down 4.26%, pointing to stock-specific dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Conference participation | Neutral | +2.0% | Announcement of TD Cowen health care conference fireside chat webcast. |
| Feb 5 | Earnings date notice | Neutral | -2.9% | Scheduling Q4 and full-year 2025 results call and webcast details. |
| Jan 28 | Research collaboration | Positive | -7.6% | MJFF-backed Parkinson’s proteomics collaboration using Iterative Mapping platform. |
| Jan 8 | Early access launch | Positive | +0.0% | Launch of Early Access Program featuring tau proteoforms assay and webinar. |
| Nov 3 | Field unit validation | Positive | +39.1% | Successful installation and multi‑month testing of first field evaluation unit. |
Product and collaboration updates often draw strong but inconsistent reactions, with at least one large upside move and one notable selloff on positive news.
Over the last several months, Nautilus has steadily advanced its single-molecule proteomics strategy. A Nov 3, 2025 update on the first Buck Institute field unit drove a 39.1% gain, underscoring enthusiasm for technical validation. The Jan 8 Early Access Program and the Jan 28 Parkinson’s collaboration, backed by a $1.6 million grant, further highlighted Iterative Mapping applications, though price reactions were muted or negative. February conference and earnings-date notices had modest impact. Today’s Voyager platform debut and late-2026 launch timeline extend this commercialization storyline.
Market Pulse Summary
The stock moved +5.2% in the session following this news. A strong positive reaction aligns with the platform’s step toward commercialization, given prior enthusiasm when Nautilus validated its field unit with a 39.1% move on Nov 3, 2025. Investors have previously rewarded clear technical milestones and external validation. However, reactions to collaborations and access programs have sometimes been muted or negative, suggesting execution and adoption remain key. Sustained gains could depend on converting the Voyager launch and Early Access work into tangible revenue and broader deployment over 2026.
Key Terms
single-molecule proteome analysis medical
proteomics medical
proteoforms medical
mass spectrometry medical
affinity-based approaches medical
machine learning-powered analysis technical
flow cells technical
biomarker medical
AI-generated analysis. Not financial advice.
• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging
• Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics
• Researchers invited to apply to the Early Access Program to use Iterative Mapping, Nautilus’ technology designed to measure billions of intact protein molecules, ahead of broader commercial availability
Nautilus Voyager™ Platform
SEATTLE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today debuted the Voyager™ Platform, which is designed to power the Iterative Mapping of up to 10 billion intact proteins and proteoforms simultaneously in a single run. With high accuracy, precision, and reproducibility, the Voyager Platform is designed to enable next-generation proteomics across any field of research.
The Voyager Platform was unveiled during the US HUPO 2026 conference in St. Louis, highlighting its ability to identify and quantify intact protein molecules with machine-learning powered analysis – all on an integrated platform with a user-friendly touchscreen interface and benchtop design that requires no special lab facility requirements. The debut follows successful installation and field testing of Nautilus’ first field evaluation unit at the Buck Institute for Research on Aging, where the Voyager Platform generated novel and highly reproducible insights into tau proteoform biology.
Proteins drive nearly all biological processes and play a central role in disease, yet existing technologies such as mass spectrometry and affinity-based approaches can measure only a fraction of the proteome and often lack the resolution needed to distinguish proteoforms. The Voyager Platform is the result of Nautilus’ unique cross-disciplinary approach to protein analysis, combining integrated reagents, fluidics, imaging, ultra-dense nano-array flow cells, and machine learning-powered algorithms, to enable Iterative Mapping and deliver on the full potential of proteomics.
"We’re excited to bring our vision of democratizing access to proteomics to fruition and share the Voyager Platform first with researchers seeking deeper insight into protein biology,” said Parag Mallick, Ph.D., Co-Founder and Chief Scientist of Nautilus. “After years of intensive development, Voyager is designed to be a benchtop tool that can help advance biomarker discovery, diagnostics, and therapeutic innovation.”
The company launched its Iterative Mapping Early Access Program in January 2026 to provide scientists with an initial opportunity to use Nautilus’ novel single-molecule proteomic analysis method and platform ahead of commercial availability. The program is currently accepting project proposals and is offered first as a fee-for-service through Nautilus Proteomics Analysis Services, followed by a limited number of Voyager instrument placements in advance of full commercial launch expected in late 2026. Accepted projects are conducted with support from Nautilus scientists who will provide guidance on data interpretation, quantification, and analysis.
The program's initial offering is the Nautilus Tau Proteoforms assay, which enables quantification of up to 768 full-length tau proteoform groups that are not accessible with standard proteomics methods. Measuring these previously inaccessible proteoforms may be critical for developing next-generation biomarkers and drug targets for neurodegenerative disorders such as Alzheimer's disease. The program is expected to expand throughout 2026 to include additional targeted proteoform analyses and broadscale proteomics applications.
“We are thrilled to extend early access to our technology to a select group of researchers who want to be at the forefront of single-molecule proteomics,” said Sujal Patel, Co-founder and CEO of Nautilus. “With Voyager, our goal is to empower scientists to ask and answer biological questions that were previously out of reach, opening the door to entirely new insights into health and disease.”
Results from Nautilus’ ongoing collaboration with the Buck Institute have established the instrument's qualification and readiness for broader research applications. Joint research results between Nautilus and the Buck Institute have provided insights into novel tau biology and are now being presented at scientific conferences.
Iterative Mapping at US HUPO 2026
In addition to the platform showcase, Nautilus will present data across multiple sessions at US HUPO, including an oral presentation on advancing proteomics through Iterative Mapping, posters detailing tau proteoform analysis in Alzheimer's disease and large-scale proteoform detection capabilities, and a sponsored lunch seminar.
On Tuesday, February 24, Nautilus’ Vice President of Scientific Engagement, Sheri Wilcox, Ph.D., and Birgit Schilling, Ph.D., Associate Professor and Director of the Mass Spectrometry Core at the Buck Institute for Research on Aging, will showcase how Iterative Mapping is transforming proteomics and enabling new insights into the role of tau biology in neurodegeneration and aging.
Lunch seminar details:
- Title: Revealing the Proteomic Landscape with Iterative Mapping
- Date: Tuesday, February 24, 2026
- Time: 12:30 PM - 1:30 PM CST
- Location: Hyatt Regency St. Louis at The Arch, Grand AB
Those interested in learning more about the data presented at US HUPO may sign up here to receive a data readout.
About the Nautilus Voyager™ Platform
The Voyager Platform employs Nautilus’ proprietary Iterative Mapping approach, which is designed to enable rapid measurement of intact single-molecule proteins and proteoforms. The platform's flow cells are designed to accommodate up to 10 billion intact protein molecules, enabling measurement across an exceptionally wide dynamic range. Iterative Mapping independently probes single protein molecules across tens to hundreds of cycles, recording unique binding patterns for each individual molecule. Machine learning algorithms then convert the resulting probe-binding patterns into confident protein and proteoform identifications. Once analysis is complete, single-molecule counts are made available for download and further visualization. The Voyager instrument is designed for operational simplicity and standard lab benchtop placement, with a guided touchscreen user interface and minimal facility requirements, without need for bespoke gas or fluidic connections.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create Voyager, a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations with respect to the potential of its platform technology, its future products, their functionality and performance or their applicability in biological research and in potentially enabling new diagnostics and therapies, and the timing of their commercial launch and/or general availability. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to scientific and technical development, which is inherently challenging and difficult to predict; we may experience material delays as a result of unanticipated events; we cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2025 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Disclosure Information
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a8d838da-9582-4e39-a727-202635ff6681
FAQ
What is the Nautilus Voyager platform announced at US HUPO 2026 (NAUT)?
When will Nautilus (NAUT) commercialize the Voyager platform?
What does Nautilus' Early Access Program for NAUT include and how does it work?
What is the Nautilus Tau Proteoforms assay and its capacity (NAUT)?
What evidence supports Voyager’s readiness for research use announced by Nautilus (NAUT)?
How can researchers access Nautilus Iterative Mapping data presented at US HUPO 2026 (NAUT)?
